Brickman, Adam M.Manly, Jennifer J.Honig, Lawrence S.Sanchez, DanurysReyes-Dumeyer, DollyLantigua, Rafael A.Lao, Patrick J.Stern, YaakovVonsattel, Jean PaulTeich, Andrew F.Airey, David C.Proctor, Nicholas KyleDage, Jeffrey L.Mayeux, Richard2024-09-112024-09-112021Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17(8):1353-1364. doi:10.1002/alz.12301https://hdl.handle.net/1805/43273Introduction: Blood-based Alzheimer's disease (AD) biomarkers provide opportunities for community studies and across ethnic groups. We investigated blood biomarker concentrations in the Washington Heights-Inwood Columbia Aging Project (WHICAP), a multi-ethnic community study of aging and dementia. Methods: We measured plasma amyloid beta (Aβ)40, Aβ42, total tau (t-tau), phosphorylated tau (p-tau)181, and p-tau217, and neurofilament light chain (NfL) in 113 autopsied participants (29% with high AD neuropathological changes) and in 300 clinically evaluated individuals (42% with clinical AD). Receiver operating characteristics were used to evaluate each biomarker. We also investigated biomarkers as predictors of incident clinical AD. Results: P-tau181, p-tau217, and NfL concentrations were elevated in pathologically and clinically diagnosed AD. Decreased Aβ42/Aβ40 ratio and increased p-tau217 and p-tau181 were associated with subsequent AD diagnosis. Discussion: Blood-based AD biomarker concentrations are associated with pathological and clinical diagnoses and can predict future development of clinical AD, providing evidence that they can be incorporated into multi-ethnic, community-based studies.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalAlzheimer's diseaseAmyloidBlood-based biomarkersNeurofilament light chainTauArticle